Scientists find a cytokine against auto-immune hepatitis

There are about 400 million patients of hepatitis in the world. Some of them are suffering from autoimmune hepatitis, a disease in which the body's immune system attacks liver cells.

A research team headed by Prof. TIAN Zhigang from the University of Science and Technology of China (USTC) recently discovered that a cytokine, a protein produced by white blood cells that act as chemical messengers between cells, could prevent mice liver from immune-mediated injury. The work, which was published at the recent issue of prestigious journal HEPATOLOGY, is applauded as providing guidance for the treatment of human autoimmune hepatitis.

Con-A-induced hepatitis is considered a good experimental model of human autoimmune hepatitis with characterized by leukocyte activation and infiltration of the liver. Using the model, Prof. Tian and colleagues found that injection of Interleukin-15 (IL-15), an important cytokine, could prevent mice from Con A-induced mortality, elevation of serum transaminase, liver necrosis, and hepatocyte apoptosis.

The researchers discovered that the mechanism for this lies in the fact that IL-15 pretreatment could decrease the NKT-derived IL-4, IL-5, and TNF- production, thereby resulting in less infiltration of eosinophils, which play a critical role in Con A-induced liver injury. Their studies indicate that IL-15 protects against Con A-induced liver injury via an NKT cell-dependent mechanism by reducing their production of IL-4, IL-5, and infiltration of eosinophils. These findings suggest that IL-15 may be of therapeutic relevance in human autoimmune-related hepatitis.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Natural killer cells lead the charge in cancer treatment innovation